Source: Annual Congress 2009 - Sarcoidosis in review
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
E. Popov, G. Kaminskaya, R. Abdullaev, V. Romanov (Moscow, Russian Federation). Evolution of systemic response in patients with pulmonary sarcoidosis of different course of the disease during anti-inflammatory treatment. Eur Respir J 2009; 34: Suppl. 53, 697

Member's Comments

No comment yet.

Related content which might interest you: Pulmonary and systemic inflammatory response in patients with pulmonary infections receiving long-term glucocorticoid therapy Source: Eur Respir J 2002; 20: Suppl. 38, 15s Year: 2002 The comparison of the manifestation of systemic inflammation in patients with minor forms of tuberculosis and pulmonary sarcoidosis Source: Annual Congress 2009 - Clinical tuberculosis Year: 2009 Effects of pulmonary rehabilitation on systemic inflammation in patients with advanced COPD Source: Eur Respir J 2005; 26: Suppl. 49, 721s Year: 2005 Systemic inflammation in patients with chronic obstructive pulmonary disease Source: Annual Congress 2013 –COPD diagnosis Year: 2013 Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 The effect of augmentation therapy on systemic and pulmonary inflammation markers in α1-antitrypsin deficiency patients Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Effects of pulmonary rehabilitation on systemic and pulmonary inflammation in COPD patients Source: Annual Congress 2010 - Exercise in COPD Year: 2010 The course of COVID-19 in pulmonary sarcoidosis patients, receiving methotrexate Source: Virtual Congress 2021 – Moving forward in various aspects of sarcoidosis Year: 2021 The natural course of systemic sclerosis patients with interstitial lung involvement Source: Eur Respir J 2005; 26: Suppl. 49, 336s Year: 2005 Different chronic obstructive pulmonary disease phenotypes, systemic inflammation and the risk of falls Source: International Congress 2016 – Exploring mechanisms in health and disease Year: 2016 Rosuvastatin influence on inflammatory and anti-inflammatory cytokines in blood in patients with chronic obstructive pulmonary disease Source: International Congress 2017 – COPD management Year: 2017 Differences in systemic immune function contribute to exacerbation susceptibility in COPD patients Source: International Congress 2015 – Modulating the immune system in COPD and asthma Year: 2015 Systemic effects in patients with chronic obstructive pulmonary disease: a role of disease duration and disease severity Source: Annual Congress 2009 - Prognosis and comorbidities in COPD Year: 2009 Community-aquired pneumonia: systemic and local inflammatory response in treatment failure Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia Year: 2008 Systemic inflammatory response in relation to disease severity and nutritional depletion in COPD Source: Eur Respir J 2004; 24: Suppl. 48, 31s Year: 2004 The efficacy of treatment with surfactant-BL (S-BL) in patients with destructive pulmonary tuberculosis Source: Annual Congress 2007 - Research perspectives: diagnosis and treatment of tuberculosis Year: 2007 Evaluation of tuberculosis risk in patients submitted to chronic immunosuppressive therapy for osteoarticular immune disease Source: Eur Respir J 2006; 28: Suppl. 50, 131s Year: 2006 Methotrexate in the treatment of the chronic form of pulmonary and extra - pulmonary sarcoidosis Source: Eur Respir J 2004; 24: Suppl. 48, 712s Year: 2004 Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (3) 2100283; 10.1183/13993003.00283-2021 Year: 2021